Clinical trial NCT05691608: MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
Official title: MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Solid Tumor
Leukemia
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2023-01-20
Enrollment: 1800
Sex: ALL
Minimum age (years): 6
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: FMG2025 continues the previous efforts to propose treatment for patients based on the molecular characteristics of their tumor at treatment failure in cancer precision medicine trials within standard of care in France. However, whereas FMG2025 is a descriptive effort providing the basis for clinical decisions, MAPPYACTS 2 will translate these findings to clinical actions. The symbiosis is critical to advance patient care.

Since 2012, the molecular profiling trials "MOlecular Screening for CAncer Treatment Optimization" (MOSCATO-01) and "MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification" (MAPPYACTS) have included pediatric and adolescent patients with recurrent or refractory malignancy that underwent on-purpose biopsy or surgical intervention. Whole Exome Sequencing of tumor and normal tissue and RNA Sequencing of tumor tissue have been applied to detect genomic alterations that could lead to an adapted targeted treatment. Furthermore, ancillary studies were associated exploring circulating tumor DNA, the immune contexture of tumors and developing Patient-Derived Xenografts (PDX).

The FMG2025 project transfers the molecular profiling of advanced pediatric cancers into a global approach that is now considered standard of care in France. Subsequent clinical recommendations and decisions will be made based on discussions with biologists, scientist and physicians in the molecular and clinical molecular tumor boards. Associated ancillary research studies and links to clinical interventional studies remain essential elements of the program to provide clinical, translational and basic research in order to improve scientific knowledge.

The program is articulated in two main parts that are closely interacting:

FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent international projects that cover the sequencing of tumor and blood samples and provide molecular reports.

The clinical study MAPPYACTS 2 that provides clinical and therapeutic discussions of the sequencing results and therapy recommendations via the clinical molecular tumor board reports. It collects molecular and comprehensive clinical data of the patients registered in FMG2025 or equivalent international projects and thereby constitutes the critical link to clinical interventional studies and its sponsors ensuring facilitated access to these trials. It also covers and coordinates ancillary research studies.

Detailed description: MAPPYACTS 2 is a prospective international multicentric clinical study to provide clinical therapeutic recommendations, to set up the molecular and comprehensive clinical database of patients with relapsed or refractory pediatric malignancies in FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent international projects, to collect the follow-up data on treatment and patients' outcome, in order to determine the outcome of the program in regard to benefit to the patient, all the patients and to health care. It will also serve as a central link to interventional study platforms and international precision medicine programs, and to cover and coordinate ancillary research studies that lead to improved treatment and outcome for children with advanced malignancies.

Subsequent clinical recommendations and decisions will be made based on discussions with biologists, scientists and physicians in the molecular and clinical molecular tumor boards run by the MAPPYACTS 2 study teams.

Associated ancillary research studies and links to clinical interventional studies are essential components of the program to perform clinical, translational and basic research in order to generate scientific knowledge and develop new treatment strategies that improve outcome of these patients. Research projects will be discussed and agreed on in the MAPPYACTS 2 study committee.

Eligibility criteria: Inclusion Criteria:

* Patient referred for sequencing of the tumor within the FMG2025 or equivalent program and written informed consent for FMG2025 "Cancers et leucémies pédiatriques en échec de traitement" or equivalent, according to local regulations
* Written informed consent of MAPPYACTS 2 to collect molecular and comprehensive clinical data on cancer diagnosis, therapies, therapy outcomes, to provide clinical therapeutic recommendations, to collect follow-up data on treatment and patients' outcome; optional written consents to perform to ancillary research studies, according to local regulations. The written consent will include access to reimbursement data from the French national health insurance through linkage with the Système National des Données de Santé (SNDS) or equivalent.
* Patient with histologically/cytologically confirmed solid tumor or leukemia which is relapsed or refractory to standard treatment and who is potentially eligible for an experimental treatment or an early phase clinical trial
* Planned tumor biopsy, surgical resection, bone marrow or blood sample or recently (preferably within the last 3 months) archived frozen tumor material available of the current recurrent or refractory disease
* Patients aged ≤ 25 years at the time of initial diagnosis
* Performance status and life expectancy \> 3 months expected to allow enrolment into an clinical trial
* Patients affiliated with a Social Security Regimen or beneficiary of the same, as per local regulatory requirements

Exclusion Criteria:

* Any concurrent illness or laboratory abnormality that, in the opinion of the investigator, is likely to interfere with the interpretation of study results
* Pregnant women

Primary outcomes:
measure: Overall survival (OS)
timeFrame: 3 years
measure: The number of additional technologies and new treatment strategies that are introduced in the care for advanced pediatric cancers through this research program.
timeFrame: 3 years
measure: The types of additional technologies and new treatment strategies that are introduced in the care for advanced pediatric cancers through this research program.
timeFrame: 3 years
Secondary outcomes:
measure: Objective response rate on treatment attributed by the molecular tumor board in the clinical trial, overall and according to the treatment decision
timeFrame: 3 years
measure: Progression-free survival (PFS)
timeFrame: 3 years
measure: 5-year overall survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Paris
country: France
facility: Gustave Roussy
state: Villejuif
city: Angers
country: France
facility: CHU Angers
city: Besançon
country: France
facility: CHU Besançon
city: Bordeaux
country: France
facility: CHU Pellegrin
city: Brest
country: France
facility: CHRU Morvan
city: Caen
country: France
facility: CHU de Caen
city: Clermont-Ferrand
country: France
facility: CHU Estaing
city: Dijon
country: France
facility: CHU Dijon François Mitterand
city: Grenoble
country: France
facility: CHU Grenoble Alpes
city: Lille
country: France
facility: Centre Oscar Lambret
city: Limoges
country: France
facility: Chu Limoges
city: Lyon
country: France
facility: IHOP
city: Marseille
country: France
facility: CHU La Timone
city: Montpellier
country: France
facility: CHU Arnaud de Villeneuve
city: Nantes
country: France
facility: CHU Nantes
city: Nice
country: France
facility: CHU de Nice
city: Paris
country: France
facility: Institut Curie
city: Poitiers
country: France
facility: CHU Poitiers
city: Reims
country: France
facility: CHU Reims- Hôpital Américain
city: Rennes
country: France
facility: CHU Rennes Hôpital Sud
city: Rouen
country: France
facility: CHU de Rouen
city: Saint-Denis
country: France
facility: CHU de La Réunion site nord
city: Strasbourg
country: France
facility: Hôpital de Hautepierre
city: Toulouse
country: France
facility: Hôpital des Enfants - CHU de Toulouse
city: Tours
country: France
facility: Hôpital Clocheville
city: Vandœuvre-lès-Nancy
country: France
facility: CHRU Nancy Hôpital Enfants
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Birgit GEOERGER, MD
role: PRINCIPAL_INVESTIGATOR
References: